Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.86 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.86 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.86 |
| ▸ | PDE5A | O76074 | 1/20 | 0.86 |
| ▸ | CA1 | P00915 | 1/20 | 0.86 |
| ▸ | CA2 | P00918 | 1/20 | 0.86 |
| ▸ | HMGCR | P04035 | 1/20 | 0.86 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.86 |
| ▸ | LCK | P06239 | 1/20 | 0.86 |
| ▸ | FYN | P06241 | 1/20 | 0.86 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.86 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.86 |
| ▸ | CA6 | P23280 | 1/20 | 0.86 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.86 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.86 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.86 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.86 |
| ▸ | TST | Q16762 | 1/20 | 0.86 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.86 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pentagalloyl Glucose SCHEMBL17019593 | 1.00 | USP2 (0.86) | USP2MAPK1TMPRSS2PDE5ACA1 | |
| Pentagalloyl Glucose SCHEMBL3147610 | 1.00 | USP2 (0.86) | USP2MAPK1TMPRSS2PDE5ACA1 | |
| Pentagalloyl Glucose SCHEMBL13286947 | 1.00 | USP2 (0.86) | USP2MAPK1TMPRSS2PDE5ACA1 | |
| Pentagalloyl Glucose SCHEMBL12129801 | 1.00 | USP2 (0.86) | USP2MAPK1TMPRSS2PDE5ACA1 | |
| Pentagalloyl Glucose SCHEMBL2787135 | 1.00 | USP2 (0.86) | USP2MAPK1TMPRSS2PDE5ACA1 | |
| Pentagalloyl Glucose SCHEMBL675693 | 1.00 | USP2 (0.86) | USP2MAPK1TMPRSS2PDE5ACA1 | |
| Pentagalloyl Glucose SCHEMBL23484369 | 1.00 | USP2 (0.86) | USP2MAPK1TMPRSS2PDE5ACA1 | |
| Pentagalloyl Glucose SCHEMBL14257930 | 1.00 | USP2 (0.86) | USP2MAPK1TMPRSS2PDE5ACA1 | |
| Pentagalloyl Glucose SCHEMBL14266926 | 1.00 | USP2 (0.86) | USP2MAPK1TMPRSS2PDE5ACA1 | |
| Pentagalloyl Glucose SCHEMBL2789358 | 1.00 | USP2 (0.86) | USP2MAPK1TMPRSS2PDE5ACA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 635 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12636145-B2 | Method for the production of crosslinked and optionally shaped tissue with selective adjustment of thickness, shape and/or flexibility | BIOTRONIK AG (CH) | 2026-05-26 | — | — | US | claimed |
| CN-122017088-A | UPLC-based construction method of characteristic spectrum of xipayi Gum fixing liquid and method for measuring content of characteristic components of UPLC-based construction method | 新奇康药业股份有限公司 | 2026-05-12 | — | — | CN | claimed |
| US-20260069621-A1 | Pentagalloyl glucose (PGG) for use in treatment of pulmonary hypertension | UNIV BERLIN CHARITE (DE) | 2026-03-12 | — | — | US | claimed |
| US-12303134-B2 | Systems for aneurysm treatment | Nectero Medical, Inc (US) | 2025-05-20 | — | — | US | claimed |
| CN-119970765-A | Pharmaceutical composition for synergistic treatment of thrombosis and application thereof | 南京中医药大学 | 2025-05-13 | — | — | CN | claimed |
| CN-116270691-B | Pharmaceutical composition | 中国医学科学院药用植物研究所 | 2025-05-09 | — | — | CN | claimed |
| WO-2025049966-A9 | METHODS AND COMPOSITIONS FOR INCREASING ROR1 EXPRESSION | INSTITUTE FOR CANCER RESEARCH D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER (US) | 2025-04-17 | — | — | WO | claimed |
| CN-119564612-A | Preparation method of pentagalloyl glucose liposome, and product and application thereof | 上海玮沐医疗科技有限公司 | 2025-03-07 | — | — | CN | claimed |
| WO-2025049966-A2 | METHODS AND COMPOSITIONS FOR INCREASING ROR1 EXPRESSION | WASIK MARIUSZ A (US) | 2025-03-06 | — | — | WO | claimed |
| US-20250066320-A1 | Active Ingredients with Sialagogue and Tingling/Fizzy Effect, and Preparations Containing Same | SYMRISE AG (DE) | 2025-02-27 | — | — | US | claimed |
| WO-2009158487-A2 | TREATMENT OF NEPHROLITHIASIS AND UROLITHIASIS USING 1,2,3,4,6-PENTA-O-GALLOYL-BETA-D-GLUCOSE (PGG) | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2009-12-30 | — | — | WO | claimed |
| US-20090170788-A1 | NOVEL USE OF 1, 2, 3, 4, 6-PENTA-O-GALLOYL-BETA-D-GLUCOSE | KIM, TAE-YOON (KR) | 2009-07-02 | — | — | US | claimed |
| WO-2007081190-A1 | NOVEL USE OF 1,2,3,4,6-PENTA-O-GALLOYL-BETA-D-GLUCOSE | BIO CLUE & SOLUTION CO., LTD. (KR) | 2007-07-19 | — | — | WO | claimed |
| US-20070148185-A1 | Novel therapeutic target for protozoal diseases | VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY | 2007-06-28 | — | — | US | claimed |
| WO-2007047579-A2 | A NOVEL THERAPEUTIC TARGET FOR PROTOZOAL DISEASES | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) | 2007-04-26 | — | — | WO | claimed |
| EP-1545554-A4 | METHODS AND COMPOSITIONS FOR TREATING DIABETES MELLITIS | UNIV OHIO (US) | 2006-06-14 | — | — | EP | claimed |
| US-20060058243-A1 | Methods and compositions for treating diabetes mellitis | OHIO UNIVERSITY | 2006-03-16 | — | — | US | claimed |
| EP-1545554-A1 | METHODS AND COMPOSITIONS FOR TREATING DIABETES MELLITIS | Ohio University (US) | 2005-06-29 | — | — | EP | claimed |
| US-20040247698-A1 | Erectile Dysfunction Treatment | VALENZUELA CORTES CARMEN MARIA (CL) | 2004-12-09 | — | — | US | claimed |
| WO-2004009094-A1 | METHODS AND COMPOSITIONS FOR TREATING DIABETES MELLITIS | OHIO UNIVERSITY (US) | 2004-01-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12636145-B2 | Method for the production of crosslinked and optionally shaped tissue with selective adjustment of thickness, shape and/or flexibility | PGF, MMP1, CTCF | USP2 1814/4885MAPK1 4726/4885TMPRSS2 1468/4885 |
| US-20260069621-A1 | Pentagalloyl glucose (PGG) for use in treatment of pulmonary hypertension | SLC5A2, SLC2A2, SLC2A1 | USP2 858/4885MAPK1 797/4885TMPRSS2 1383/4885 |
| US-20060058243-A1 | Methods and compositions for treating diabetes mellitis | IAPP, GCG, MTPN | USP2 4592/4885MAPK1 1019/4885TMPRSS2 3455/4885 |
| US-20250066320-A1 | Active Ingredients with Sialagogue and Tingling/Fizzy Effect, and Preparations Containing Same | TAS2R5, TAS2R7, TAS2R8 | USP2 4458/4885MAPK1 3379/4885TMPRSS2 3144/4885 |
| US-20040247698-A1 | Erectile Dysfunction Treatment | PDE3A, PDE3B, PDE12 | USP2 2078/4885MAPK1 2445/4885TMPRSS2 2417/4885 |
| US-20090170788-A1 | NOVEL USE OF 1, 2, 3, 4, 6-PENTA-O-GALLOYL-BETA-D-GLUCOSE | UGGT1, G6PD, HK1 | USP2 2319/4885MAPK1 286/4885TMPRSS2 3762/4885 |
| US-12303134-B2 | Systems for aneurysm treatment | PLG, GANAB, PGD | USP2 671/4885MAPK1 1209/4885TMPRSS2 1962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.